BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 30070357)

  • 1. Actinic keratosis - review for clinical practice.
    de Oliveira ECV; da Motta VRV; Pantoja PC; Ilha CSO; Magalhães RF; Galadari H; Leonardi GR
    Int J Dermatol; 2019 Apr; 58(4):400-407. PubMed ID: 30070357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Not Available].
    Herms F
    Ann Dermatol Venereol; 2019 May; 146 Suppl 2():IIS22-IIS30. PubMed ID: 31133226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A trial-based cost-effectiveness analysis of topical 5-fluorouracil vs. imiquimod vs. ingenol mebutate vs. methyl aminolaevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherlands.
    Jansen MHE; Kessels JPHM; Merks I; Nelemans PJ; Kelleners-Smeets NWJ; Mosterd K; Essers BAB
    Br J Dermatol; 2020 Oct; 183(4):738-744. PubMed ID: 31961446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solar keratoses: photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies.
    Schmitt AR; Bordeaux JS
    Clin Dermatol; 2013; 31(6):712-7. PubMed ID: 24160275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Network meta-analysis of the outcome 'participant complete clearance' in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review.
    Gupta AK; Paquet M
    Br J Dermatol; 2013 Aug; 169(2):250-9. PubMed ID: 23550994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.
    Tolley K; Kemmett D; Thybo S; Nasr R; Smethurst H
    Eur J Health Econ; 2016 Apr; 17(3):287-304. PubMed ID: 25795391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnosis and treatment of actinic keratosis].
    Isoherranen K; Koskenmies S; Overmark M; Ylitalo L; Saksela O; Pitkänen S
    Duodecim; 2015; 131(9):863-70. PubMed ID: 26237885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current therapies for actinic keratosis.
    Dianzani C; Conforti C; Giuffrida R; Corneli P; di Meo N; Farinazzo E; Moret A; Magaton Rizzi G; Zalaudek I
    Int J Dermatol; 2020 Jun; 59(6):677-684. PubMed ID: 32012240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current management of actinic keratoses.
    Shoimer I; Rosen N; Muhn C
    Skin Therapy Lett; 2010 May; 15(5):5-7. PubMed ID: 20505896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary management of actinic keratosis.
    Navarrete-Dechent C; Marghoob AA; Marchetti MA
    J Dermatolog Treat; 2021 Aug; 32(5):572-574. PubMed ID: 31621454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Field cancerization: from molecular basis to selective field-directed management of actinic keratosis.
    Philipp-Dormston WG
    Curr Probl Dermatol; 2015; 46():115-21. PubMed ID: 25561215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addressing the Challenges of Treating Actinic Keratosis.
    Kircik LH
    J Drugs Dermatol; 2019 May; 18(5):s160. PubMed ID: 31141861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy of actinic keratosis.
    Berman B; Amini S; Valins W; Block S
    Expert Opin Pharmacother; 2009 Dec; 10(18):3015-31. PubMed ID: 19925043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy.
    Neri L; Peris K; Longo C; Calvieri S; Frascione P; Parodi A; Eibenschuz L; Bottoni U; Pellacani G;
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):93-107. PubMed ID: 29920789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Field Cancerization Therapies for Management of Actinic Keratosis: A Narrative Review.
    Jetter N; Chandan N; Wang S; Tsoukas M
    Am J Clin Dermatol; 2018 Aug; 19(4):543-557. PubMed ID: 29582369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conventional treatment of actinic keratosis: an overview.
    Peris K; Fargnoli MC
    Curr Probl Dermatol; 2015; 46():108-14. PubMed ID: 25561214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Not Available].
    Paugam C; Dréno B
    Ann Dermatol Venereol; 2019 May; 146 Suppl 2():IIS31-IIS35. PubMed ID: 31133228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy of actinic keratosis: an update.
    Berman B; Amini S
    Expert Opin Pharmacother; 2012 Sep; 13(13):1847-71. PubMed ID: 22888917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-melanoma Skin Cancer in Canada Chapter 3: Management of Actinic Keratoses.
    Poulin Y; Lynde CW; Barber K; Vender R; Claveau J; Bourcier M; Ashkenas J;
    J Cutan Med Surg; 2015; 19(3):227-38. PubMed ID: 25926621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoeconomic analysis of the treatment of multiple actinic keratoses.
    Gold MH
    J Drugs Dermatol; 2008 Jan; 7(1):23-5. PubMed ID: 18246694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.